A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

ClinicalTrials.gov ID: NCT06090539

Public ClinicalTrials.gov record NCT06090539. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 8, 2026, 7:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)

Study identification

NCT ID: NCT06090539
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 308 participants

Conditions and interventions

Conditions

Relapsed/Refractory Non-Hodgkin Lymphoma

Interventions

BMS-986458 Drug
Glofitamab/Obinutuzumab Drug
Mosunetuzumab Drug
Rituximab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 28, 2023
Primary completion: Oct 27, 2027
Completion: Oct 27, 2028
Last update posted: Apr 13, 2026

2023 – 2028

United States locations

U.S. sites: 14
U.S. states: 11
U.S. cities: 13

Facility	City	State	ZIP	Site status
Mayo Clinic in Arizona - Phoenix	Phoenix	Arizona	85054	Recruiting
City of Hope Comprehensive Cancer Center	Duarte	California	91010	Recruiting
Local Institution - 0068	Jacksonville	Florida	32224	Not yet recruiting
Moffitt Cancer Center	Tampa	Florida	33612	Recruiting
Local Institution - 0014	Fairway	Kansas	66205	Not yet recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Mayo Clinic in Rochester, Minnesota	Rochester	Minnesota	55905	Recruiting
Local Institution - 0124	Omaha	Nebraska	68105	Not yet recruiting
Local Institution - 0047	Lake Success	New York	11042	Completed
Local Institution - 0037	New York	New York	10016	Not yet recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
Local Institution - 0040	Pittsburgh	Pennsylvania	15232	Not yet recruiting
Local Institution - 0045	Providence	Rhode Island	02903	Not yet recruiting
Local Institution - 0024	Milwaukee	Wisconsin	53226	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06090539, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 13, 2026 · Synced May 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06090539 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →